Momenta Pharmaceuticals (Momenta Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Jun. 2020)

View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Momenta Pharmaceuticals's interest expense for the three months ended in Jun. 2020 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2020 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Momenta Pharmaceuticals's Operating Income for the three months ended in Jun. 2020 was $ -57.38 Mil. Momenta Pharmaceuticals's Interest Expense for the three months ended in Jun. 2020 was $ 0.00 Mil. GuruFocus does not calculate Momenta Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Momenta Pharmaceuticals Interest Expense Historical Data

The historical data trend for Momenta Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Interest Expense Chart

Momenta Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Interest Expense

Get a 7-Day Free Trial

-2.02

Momenta Pharmaceuticals Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Momenta Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Momenta Pharmaceuticals (NAS:MNTA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Momenta Pharmaceuticals's Interest Expense for the three months ended in Jun. 2020 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2020 was $-57.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2020 was $31.35 Mil.

Momenta Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2020 is calculated as

GuruFocus does not calculate Momenta Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Momenta Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.momentapharma.com

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Executives

Bruce Downey	director
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner	director	C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo	officer: SVP, Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon	officer: Chief Financial & Bus. Officer	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier	officer: Chief Mfg and Program Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello	officer: Chief HR and Inf. Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning	officer: Chief Scientific Officer	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska	officer: Chief Accounting Officer (PAO)	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler	director, officer: President & CEO